Strikingly, the SDT treatment described here appears to disrupt this pattern, since the results demonstrate a significant decrease in percentages of CD4+(CD8−)CD25+FOXP3+ and CD4+(CD8−)CD25+FOXP3+CTLA-4+ Tregs in tumours isolated from mice treated with the SDT compared to the untreated, as soon as day 4 after treatment (Fig. 6A), with an effect size for both populations considered as large (Supplementary Table S2). The gene discussed is FOXP3; the disease is neoplasm.